

**DONCASTER and BASSETLAW AREA PRESCRIBING COMMITTEE
MINUTES from Thursday 28th July 2016**

Present:

<u>NHS Doncaster CCG</u>		<u>RDaSH FT</u>		<u>Doncaster LPC</u>	
Dr David Crichton – (APC Chair)	✓	Mr Stephen Davies – Chief Pharmacist RDaSH FT	✓	Mr Paul Chatterton – LPC Representative	✓
Mr Mark Randerson- Head of Medicines Management (NHSD-MMT)	✓	Mr Andrew Houston - Senior Mental Health Pharmacist		Mr M Ahmed - Deputy	
Mrs Gill Bradley – Deputy Head of Medicines Management (NHSD-MMT)	✓	Dr Eric Dale - Consultant Psychiatrist RDaSH FT	✓	<u>DBHFT</u>	
Dr Rachel Sykes – NHS Doncaster GP	✓	Ms Anne Burton – Non Medical Prescriber Representative (RDaSH DCIS)		Mr Andrew Barker – Chief Pharmacist DBHFT	
<u>NHS Bassetlaw CCG</u>		Ms Julie Hall - Non Medical Prescriber Representative (RDaSH DCIS)		Mr Lee Wilson – Consultant Pharmacist DBHFT	
Mr Rob Wise – Medicines Management Lead Pharmacist (BCCG)	✓	<u>Doncaster LMC</u>		Dr Mahmoud Al Khoffash – Medical Director representative DBHFT	
		Dr Dean Eggitt- LMC Secretary	✓		
		Mr D Gibbons- LMC Deputy		<u>FCMS (When necessary)</u>	
				Mrs Gillian Gregory	

Minutes Only :- Dr Mark Pickering Doncaster Offender Health, Chair prisons D&T Committee

Dr Rupert Suckling & Mr Victor Joseph Public Health England

Mrs Gillian Gregory FCMS

In Attendance: Angie Machin – Minute Secretary (NHS Doncaster-MMT)

Agenda Item	Discussion Points	Action By
07/16/1	Apologies Apologies were received from Dr M Al Khoffash, Mrs A Burton, Mr L Wilson	
07/16/2	Declarations of Interest, Gifts or Hospitality No additional declarations were received	
07/16/3	Minutes of last meeting The minutes of the last meeting held on the 30 th June 2016 were	

	agreed as a true and accurate record and will be made available on the medicines management website.	
07/16/4.1	Matters Arising	
11/15/8.4	Potential development of SCP/Pathway update for the management of Adult ADHD There is no progress to report; a full update will be given at the next APC meeting.	RDaSHFT
06/16/8.1	Dementia: supporting people with dementia and their carer's in health and social care A meeting has been arranged on 7 th September with Dr K Wagstaff Clinical Lead for Dementia and Mr W Goddard CCG Integrated Lead for Dementia. NHSD-MMT will give an update on the discussion at the APC meeting in June and ask for their thoughts on the implications of the NICE CG42 document. The Committee will be informed of the outcome following the meeting.	NHSD-MMT(GB)
06/16/8.2	Sharps bins It has now been confirmed that the current system for the receiving and collection of Sharps bins will continue.	
07/16/5	Traffic Light – Drugs for Review All drugs for review were agreed as proposed, will be updated on the traffic light system and the details included in the next APC informer. Obinutuzumab (Gazyvaro) used in both Chronic lymphocytic leukaemia (CLL) & Follicular Lymphoma (FL) remains Red 1. Sacubitril/valsartan (Entresto) used in Chronic Heart failure will remain as Red 1, 2. This will be reviewed again in January 2017, this is to allow time to establish the drugs place in therapy and also determine the pathway for initiation and continuation of the treatment. NHSD-MMT will liaise with DBHFT Drugs & Therapeutic Committee. Golimumab (Simponi) used in Polyarticular juvenile idiopathic arthritis has been categorised as Red 1,2,3, Degludec / liraglutide (Xultophy) used in Type 2 Diabetes has been categorised as Green – G, refer to the formulary	NHSD-MMT(AM) NHSD-MMT(MR)
07/16/6	APC Officers actions All officers actions were agreed as proposed, will be updated on the traffic light system.	NHSD-MMT(AM)

07/16/7	<p>Traffic Light – Additions for Consideration</p> <p>All additions for consideration were agreed as proposed, will be updated on the traffic light system and the details included in the next APC informer.</p> <p>Daratumumab (DARZALEX) used in Multiple Myeloma has been categorised as Red 1,2,3</p> <p>Emtricitabine, Rilpivirine, Tenofovir, Alafenamide (Odefsey) used in HIV has been categorised as Red 1,2</p> <p>Conjugated Oestrogens/ Bazedoxifene (DUAVIVE) used in Oestrogen deficiency symptoms in postmenopausal women has been referred to the FLG it will therefore be categorised as Grey 4</p> <p>Eftrenonacog alfa (ALPROLIX) used in Haemophilia B has been categorised as Red 1</p> <p>Sofosbuvir/Velpatasvir (Epclusa) used in Hepatitis C has been categorised as Red 1</p>	NHSD-MMT(AM)
07/16/8	New Business	
07/16/8.1	<p>Nottinghamshire APC position statement attached for Liothyronine.</p> <p>The Committee was asked to consider the categorisation of Liothyronine, Amber-G (non-formulary).</p> <p>The Nottinghamshire APC has categorised Liothyronine as Grey for hypothyroidism.</p> <p>The Committee acknowledged that RDaSH FT do on occasion use the drug for mental health conditions and the suggestion to ascertain its place in therapy was agreed with RDaSH FT. NHSD-MMT agreed to raise the issue of prescribing for hypothyroidism at the DBHFT Drugs & Therapeutic Committee meeting. The Committee will discuss further following these actions.</p>	RDaSHFT NHSD-MMT (MR)
07/16/8.2	<p>Sheffield Teaching Hospitals Shared Care for Growth Hormone</p> <p>Sheffield Teaching Hospital (STH) is trying to identify some Doncaster patients taking growth hormones lost to follow up within the Sheffield Shared Care system. STH is producing a letter to send to the CCG accepting responsibility for the situation and requesting support from Doncaster and Bassetlaw GPs in identifying patients. . Once received MMT will run some data searches to identify where prescribing is active in Doncaster & Bassetlaw and will then share this information with appropriate surgeries to ensure the review process can be resumed.</p>	NHSD-MMT (MR)
07/16/8.3	<p>Anti-epileptic drugs</p> <p>Mr S Emmerson DCCG Senior Contracting Manager for STH has recently received a letter from Dr Richard Grunewald, Clinical Director of Neurosciences that is intended to be sent to GP's in Doncaster advising them to adhere to the Traffic Light System in Sheffield and refer to the Sheffield Shared Care paperwork when</p>	NHSD-MMT(MR)

	<p>requested to prescribe anti-epileptic drugs. The Committee considered:</p> <ul style="list-style-type: none"> • The appropriateness of the TLS status of the anti-epileptic drugs • The advantages and disadvantages of Doncaster and Bassetlaw adopting the Sheffield shared care protocol • Future actions <p>Sheffield APG had not been aware of the letter.</p> <p>Following discussion the Committee did feel that the existing categorisation (Amber-G) of the drugs remained suitable. The Committee was also informed that as part of the RightCare workstreams the CCG is looking at epilepsy and a pathway review; this may impact on the position of prescribing moving forward.</p> <p>The Committee will recommend that the response to Dr Grunewald should highlight the following:</p> <ul style="list-style-type: none"> • The STH letter does not reflect the Principles of Shared Care document agreed with all South Yorkshire and Bassetlaw CCG's. • The Committee continue to feel that the Sheffield shared care paperwork is not suitable for use across Doncaster and Bassetlaw • The Sheffield "shared care" paperwork is actually a transfer/discharge process as patients are not always kept under specialist review. • The pathway for managing patients with epilepsy requires clarification • Development or adoption of shared care paperwork without an established safe care pathway, into which it can be embedded, is not recommended. <p>This message will be shared with Mr M Young, DCCG Lead for Neurology RightCare group, and Mr S Emmerson, DCCG Contract Manager for STH.</p>	
07/16/8.4	<p>Update on the management of patients prescribed anti-psychotic medication</p> <p>The work is progressing and the criteria for referring in to Secondary Care and discharging patients in to Primary Care is being developed. The process for Primary Care to make an urgent referral back into the specialist service will also be incorporated into the model. The Committee was advised that RDaSHFT is looking at using the TPP software as a future IT development and therefore potentially may use read codes that match those used in Primary Care. Further updates will be brought back to the Committee.</p>	NHSD- MMT(GB)
07/16/8.5	Use of bisphosphonates in breast cancer	NHSD-

	<p>Further to previous discussions and SY&B meetings the Committee received a suite of papers on the implementation of a pathway to introduce bisphosphonates as part of the routine management of post-menopausal women with breast cancer. The Committee agreed that discussion of these papers, in the first instance, would be more appropriately undertaken at the CCG Medicines Management Group. Further updates will be brought back to the Committee.</p>	MMT(GB)
07/16/8.6	<p>Gluten Free Guidance</p> <p>The updated guidance was received by the Committee for information. This has been updated in collaboration with the Dietetic Department at DBHFT. The Committee did discuss how Gluten Free products have been restricted further or stopped in other areas and the risks involved in doing this.</p>	
07/16/8.7	<p>DCCG Prescribing Gain share Scheme</p> <p>The Committee was informed of the scheme that has been offered to GP's. Over 30 surgeries have signed up to the scheme so far. The intention of sharing the launch of the scheme was to ensure that Doncaster health partners were aware.</p>	
07/16/8.8	<p>Formulary inhalers For Asthma and COPD</p> <p>The poster to support the formulary inhaler choices was shared with the Committee for information. The poster has been referenced in the T@blet and is on the medicines management website Asthma & COPD Choices and all surgeries have received it.</p>	
07/16/9	<p>DBHFT D&TC Update No minutes available</p>	
07/16/10	<p>Formulary Liaison Group Update No minutes available</p>	
07/16/11	<p>Doncaster Prisons Drug & Therapeutic Committee No minutes available</p>	
07/16/12	<p>RDASH FT & Medicines Management Committee update No minutes available</p>	
07/16/13	<p>Barnsley Area Prescribing Committee Update No minutes available</p>	
07/16/14	<p>Rotherham Area Prescribing Committee update No minutes available</p>	
07/16/15	<p>Sheffield Area Prescribing Committee Update The minutes of the meeting held on 19th May 2016 were received by the Committee</p>	
07/16/16	<p>Nottinghamshire Area Prescribing Committee Update The minutes of the meeting held on 17th March 2016 were received by the Committee</p>	
07/16/17	<p>Any Other Business Mr L Wilson & Dr D Eggitt have given apologies for the August meeting.</p>	

07/16/18	<p>Date, time & venue of next meeting 12 noon prompt Thursday 25th August 2016 in Meeting Room 3 Sovereign House</p>	
	<p>12 noon prompt Thursday 29th September 2016 in Meeting Room 3 Sovereign House</p> <p>12 noon prompt Thursday 27th October 2016 in Meeting Room 3 Sovereign House</p> <p>12 noon prompt Thursday 24th November 2016 in Meeting Room 3 Sovereign House</p> <p>12 noon prompt Thursday 29th December 2016 in Meeting Room 3 Sovereign House</p> <p>12 noon prompt Thursday 26th January 2017 in Meeting Room 3 Sovereign House</p> <p>12 noon prompt Thursday 23rd February 2017 in Meeting Room 3 Sovereign House</p> <p>12 noon prompt Thursday 30th March 2017 in Meeting Room 3 Sovereign House</p> <p>12 noon prompt Thursday 27th April 2017 in Meeting Room 3 Sovereign House</p> <p>12 noon prompt Thursday 25th May 2017 in Meeting Room 3 Sovereign House</p> <p>12 noon prompt Thursday 29th June 2017 in Meeting Room 3 Sovereign House</p> <p>12 noon prompt Thursday 27th July 2017 in Meeting Room 3 Sovereign House</p> <p>12 noon prompt Thursday 31st August 2017 in Meeting Room 3 Sovereign House</p> <p>12 noon prompt Thursday 28th September 2017 in Meeting Room 3 Sovereign House</p>	